Abcam Plc (ABCZY) 8.8740 $ABCZY
Abcam's New Anti-PD-L1 Antibody Enables Deeper Insights into Cancer Immunology Research
Business Wire - Tue Oct 06, 5:12AM CDT
Abcam plc, a global leader in the supply of life sciences research tools, today announced the launch of its anti-PD-L1 primary antibody (clone 28-
. Produced using Abcam's RabMAb(R) recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research.
ABC: 92.84 (-0.70)
G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Fri Jul 17, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h8sv7h/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTP?S binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter's Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd. The global GPCRs market is segmented as follows: GPCRs Market, by Assay Type - Calcium Level Detection Assays - GTPyS Binding Assays - cGMP Assays - Reporter Gene Assays - Receptor Internalization Assay - cAMP Assays GPCRs Market, by Therapeutic Area - Cardiovascular System - Central Nervous System - Respiratory System - Immune System - Reproductive System - Oncology - Others For more information visit http://www.researchandmarkets.com/research/h8...in_coupled
SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), QGEN: 25.90 (+0.18), PKI: 48.19 (+0.31)
Oxidative Stress Assay Market by Product, Test Type, Technology, End Users - Global Forecast to 2020
M2 - Fri May 29, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8b9r9d/oxidative_stress) has announced the addition of the "Oxidative Stress Assay Market by Product (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology (ELISA, Chromatography, Flow Cytometry), End Users - Global Forecast to 2020" report to their offering. The global oxidative stress assay market is expected to reach $736.85 Million by 2020 from $452.36 Million in 2015, growing at a CAGR of 10.25% from 2015 to 2020 Oxidative stress assays is a well-established method for screening and detecting markers of oxidative stress in cultured cells. The assay kits gives more relevant biological information compared to that obtained by the measurement of individual components, hence it is a great tool for evaluating the capacity to counter oxidative stress. With rapid innovations in oxidative stress assays technologies, researchers are now able to detect oxidative stress biomarkers very easily. Furthermore, with rapid developments in the field of oxidative stress assays, researchers are equipped with new technological advances to generate high accuracy and efficiency in the testing of oxidative stress. The report provides a granular understanding of the oxidative stress assay market. This report segments the global oxidative stress assay market on the basis of products, test types, technologies, end users, and regions. The product segments included in this report are consumables, instruments, and services. On the basis of test types, the market is segmented into indirect assays, antioxidant capacity assays, enzyme-based assays, and reactive oxygen species (ROS)-based assays. The end-user segments included in this report are pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and contract research organizations. The report maps each test type and product segment in 11 geographic and regional segments. The major players in the oxidative stress assay market include Abcam plc (U.K.), AMS Biotechnology (U.K.), BioVision, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Enzo Biochem (U.S.), Merck and Co., Inc. (U.S.), Oxford Biomedical Research (U.S.), QIAGEN N.V. (Netherlands), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Oxidative Stress Assays Market, By Product 8 Oxidative Stress Assays Market, By Technology 9 Oxidative Stress Assays Market, By Test Type 10 Oxidative Stress Assays Market, By End User 11 Oxidative Stress Assays Market, By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/8b...ive_stress
ENZ: 3.75 (+0.04), SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), QGEN: 25.90 (+0.18)
Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019
M2 - Mon May 18, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49qvgs/antibody) has announced the addition of the "Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019" report to their offering. The global antibody production market is expected to reach $2.572 Billion in 2019 from $1.425 Billion in 2014, growing at a CAGR of 12.5%. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the fastest rate during the forecast period. Antibodies, also known as immunoglobulins, are specialized immune proteins produced when an antigen enters the body. Antibodies are produced by the immune system in response to the presence of foreign antigens or targets such as viruses and bacteria. Antibodies can be produced using hybridoma and hybridoma-free techniques. The major types of antibodies produced are monoclonal and polyclonal antibodies. The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions. By product, this market is categorized into equipment and consumables. In 2014, the consumables segment accounted for the largest share of this market. This segment is expected to grow at the fastest rate during the forecast period (2014 to 2019). On the basis of type, this market is divided into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for the largest share of the market. However, the polyclonal antibodies segment is expected to grow at the fastest rate during the forecast period. The globa market, by technology, is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for the largest share of the market. However, the hybridoma-free technology segment is expected to grow at the fastest rate during the forecast period. This market, by end user, is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. The biotechnology and pharmaceutical companies segment is the largest and fastest-growing segment of the antibody production market. The key factors that are expected to spur the growth of this market are increasing demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market. Some of the major players in the global market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany). For more information visit http://www.researchandmarkets.com/research/49qvgs/antibody
SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), AMGN: 149.59 (-0.31)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 149.90 (+0.42), COO: 137.62 (-4.37), SNN: 34.67 (-0.43), VCYT: 6.50 (+0.10), ABAX: 46.25 (+1.44), DYSL: 1.90 (+0.02), VOLC: 17.99 (+0.01), CLLS: 26.61 (-0.16), COHR: 57.81 (-0.32), HRC: 53.23 (+0.56)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.34 (-0.02), GBSNU: 16.22 (-0.28), MZOR: 11.60 (+0.03), FEIC: 77.20 (-0.02), ZLTQ: 31.72 (+0.04), IART: 58.79 (+0.44), BVX: 2.10 (+0.04)
GeoSpock Limited Completes £782,500 ($1,245,350) Fundraising and Enters the TechStars Global Startup Accelerator
PR Newswire - Mon Nov 10, 3:47AM CST
UK geosearch tech firm raises cash to commercialise its GeoWarp(TM), Collide(TM) and Collide App Designer(TM) platforms that enable businesses wishing to take advantage of growing trends in the internet-of-things, big-data and multi-dimensional, real-time geospatial experiences.
ABC: 92.84 (-0.70)
Abcam's New Anti-PD-L1 Antibody Enables Deeper Insights into Cancer Immunology Research
Business Wire - Tue Oct 06, 5:12AM CDT
Abcam plc, a global leader in the supply of life sciences research tools, today announced the launch of its anti-PD-L1 primary antibody (clone 28-
. Produced using Abcam's RabMAb(R) recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research. ABC: 92.84 (-0.70)
G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022
M2 - Fri Jul 17, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h8sv7h/gprotein_coupled) has announced the addition of the "G-Protein Coupled Receptors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022" report to their offering. The global GPCRs market has been segmented based on of assay type, therapeutic area, and geography. Based on assay type, the GPCRs market has been categorized into six major segments: cAMP assays, calcium level detection assays, GTP?S binding assays, reporter gene assays, receptor internalization assays, and cGMP assays. The market for these segments has been extensively analyzed based on of their effectiveness, usefulness, sales, and geographic presence. Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. In terms of therapeutic areas, the market has been segmented into seven categories: cardiovascular system, central nervous system (CNS), respiratory system, immune system, reproductive system, oncology, and others (abdominal, urinary, orthopedics, etc.). Market revenue in terms of USD million for the period between 2012 and 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 are provided for all the segments, considering 2013 as the base year. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that have strong impact on the GPCRs market currently and could influence the market in future as well. The market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. Porter's Five Forces analysis is also explained in this section to understand the GPCRs market considering different parameters that have an impact on the sustainability of the companies operating in the GPCRs market. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Major players profiled in this report include Thermo Fisher Scientific, Inc., EMD (Merck) Millipore, Becton, Dickinson and Company, PerkinElmer, Inc., Cisbio Bioassays, Enzo Life Sciences, Inc., DiscoveRx Corporation, Sigma-Aldrich Corporation, QIAGEN N.V., Promega Corporation, Abcam plc, and HD Biosciences Co. Ltd. The global GPCRs market is segmented as follows: GPCRs Market, by Assay Type - Calcium Level Detection Assays - GTPyS Binding Assays - cGMP Assays - Reporter Gene Assays - Receptor Internalization Assay - cAMP Assays GPCRs Market, by Therapeutic Area - Cardiovascular System - Central Nervous System - Respiratory System - Immune System - Reproductive System - Oncology - Others For more information visit http://www.researchandmarkets.com/research/h8...in_coupled
SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), QGEN: 25.90 (+0.18), PKI: 48.19 (+0.31)
Oxidative Stress Assay Market by Product, Test Type, Technology, End Users - Global Forecast to 2020
M2 - Fri May 29, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8b9r9d/oxidative_stress) has announced the addition of the "Oxidative Stress Assay Market by Product (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology (ELISA, Chromatography, Flow Cytometry), End Users - Global Forecast to 2020" report to their offering. The global oxidative stress assay market is expected to reach $736.85 Million by 2020 from $452.36 Million in 2015, growing at a CAGR of 10.25% from 2015 to 2020 Oxidative stress assays is a well-established method for screening and detecting markers of oxidative stress in cultured cells. The assay kits gives more relevant biological information compared to that obtained by the measurement of individual components, hence it is a great tool for evaluating the capacity to counter oxidative stress. With rapid innovations in oxidative stress assays technologies, researchers are now able to detect oxidative stress biomarkers very easily. Furthermore, with rapid developments in the field of oxidative stress assays, researchers are equipped with new technological advances to generate high accuracy and efficiency in the testing of oxidative stress. The report provides a granular understanding of the oxidative stress assay market. This report segments the global oxidative stress assay market on the basis of products, test types, technologies, end users, and regions. The product segments included in this report are consumables, instruments, and services. On the basis of test types, the market is segmented into indirect assays, antioxidant capacity assays, enzyme-based assays, and reactive oxygen species (ROS)-based assays. The end-user segments included in this report are pharmaceutical and biotechnology companies, academic research institutes, clinical laboratories, and contract research organizations. The report maps each test type and product segment in 11 geographic and regional segments. The major players in the oxidative stress assay market include Abcam plc (U.K.), AMS Biotechnology (U.K.), BioVision, Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Enzo Biochem (U.S.), Merck and Co., Inc. (U.S.), Oxford Biomedical Research (U.S.), QIAGEN N.V. (Netherlands), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Oxidative Stress Assays Market, By Product 8 Oxidative Stress Assays Market, By Technology 9 Oxidative Stress Assays Market, By Test Type 10 Oxidative Stress Assays Market, By End User 11 Oxidative Stress Assays Market, By Region 12 Competitive Landscape 13 Company Profiles For more information visit http://www.researchandmarkets.com/research/8b...ive_stress
ENZ: 3.75 (+0.04), SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), QGEN: 25.90 (+0.18)
Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019
M2 - Mon May 18, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49qvgs/antibody) has announced the addition of the "Antibody Production Market by Product, Type, Technology & by End-User - Analysis & Global Forecast to 2019" report to their offering. The global antibody production market is expected to reach $2.572 Billion in 2019 from $1.425 Billion in 2014, growing at a CAGR of 12.5%. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the fastest rate during the forecast period. Antibodies, also known as immunoglobulins, are specialized immune proteins produced when an antigen enters the body. Antibodies are produced by the immune system in response to the presence of foreign antigens or targets such as viruses and bacteria. Antibodies can be produced using hybridoma and hybridoma-free techniques. The major types of antibodies produced are monoclonal and polyclonal antibodies. The global antibody production market is segmented on the basis of products, types, technologies, end users, and regions. By product, this market is categorized into equipment and consumables. In 2014, the consumables segment accounted for the largest share of this market. This segment is expected to grow at the fastest rate during the forecast period (2014 to 2019). On the basis of type, this market is divided into monoclonal and polyclonal antibodies. In 2014, the monoclonal antibodies segment accounted for the largest share of the market. However, the polyclonal antibodies segment is expected to grow at the fastest rate during the forecast period. The globa market, by technology, is segmented into hybridoma and hybridoma-free technologies. In 2014, the hybridoma technology segment accounted for the largest share of the market. However, the hybridoma-free technology segment is expected to grow at the fastest rate during the forecast period. This market, by end user, is segmented into biotechnology and pharmaceutical companies, diagnostic laboratories, and research institutes. The biotechnology and pharmaceutical companies segment is the largest and fastest-growing segment of the antibody production market. The key factors that are expected to spur the growth of this market are increasing demand for monoclonal antibodies globally and rising R&D expenditure of pharmaceutical and biotechnology companies. Moreover, emerging markets of India and China, rising demand for protein therapeutics, and increasing risk of pandemics and infectious diseases are likely to increase the demand for equipment and consumables used in antibody production. However, high cost of primary antibodies is likely to restrain the growth of this market. Some of the major players in the global market include GE Healthcare (U.K.), Thermo Fisher Scientific, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Sartorius AG (Germany), Merck Millipore (U.S.), Abcam plc (U.K.), Amgen (U.S.), Sanofi S.A. (France), Rockland Immunochemicals, Inc. (U.S.), and Roche Applied Science (Germany). For more information visit http://www.researchandmarkets.com/research/49qvgs/antibody
SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07), AMGN: 149.59 (-0.31)
100 M&A Focused Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7d4bk7/manda_focused) has announced the addition of the "M&A Focused Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This report newly launched report identifies 100 M&A Focused medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Alliances and partnerships have traditionally been used to help companies reduce their funding and resource burden and provide potential upside. These non-dilutive sources of funding can take many forms and warrant a second look in the light of today's difficult economy. A panel of seasoned medical device executives will analyze several recent partnering deals and contemplate their usefulness as alternative funding sources. Practical take-away include: how to integrate product co-development into your innovation strategy, understanding the key differences in structuring partnership deals with large and small companies and universities and/or research centers, understanding the pitfalls, risks and opportunities that these partnering models present, and understanding how to leverage these relationships to create win-win scenarios to the benefit all participants. M&A environment in 2015 is anticipated to continue its strong growth trends. Strategic and private equity acquisition appetites for strong healthcare companies continue to grow and this offers tremendous liquidity opportunities for business owners. As strategic acquirers become increasingly aggressive in their pursuit of new sources of growth, the robust capital markets welcome the next wave of growth companies. Despite significant challenges in reimbursement and other operating factors, many healthcare providers continue to grow profitably by scaling their businesses. While this growth comes at a significant cost to gross margins, we see efficient companies continuing to generate strong overall profits and hence, attractive acquisition opportunities. Report Highlights: - M&A Focused 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of M&A Focused medical devices/technology/supplies companies with foreign companies - International presence of M&A Focused medical devices/technology/supplies companies - Key R&D activities by M&A Focused medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of M&A Focused Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 M&A Focused Medical Devices/Technology/Supplies Companies 3: Key News of M&A Focused Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of M&A Focused Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by M&A Focused Medical Devices/Technology/Supplies Companies 6: International Presence of M&A Focused Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of M&A Focused Medical Devices/Technology/Supplies Companies Companies Mentioned Sample list of company names included in this industry report: - 3M Company (United States) - Abaxis Inc (United States) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alfresa Pharma Corp (Japan) - Andon Health Company Limited (China) - Angiodynamics, Inc. (United States) - Anteo Diagnostics Limited (Australia) - Atcor Medical Holdings Ltd (Australia) - Azure Healthcare Ltd. (Australia) - Bio Rad Laboratories Incorporated (United States) - Bruker Corporation (United States) - Capitol Health Ltd (Australia) - Carefusion Corporation (United States) - Carl Zeiss Co., Ltd. (Japan) - Cellectis SA (France) - Coherent Incorporated (United States) - Cooper Companies Inc. (United States) - Corgenix Medical Corporation (United States) - Dynasil Corporation Of America (United States) - Heartware International Inc (Australia) - Hill-Rom Holdings, Incorporation (United States) - Jeol Limited (Japan) - Paragon Care Limited (Australia) - Smith & Nephew PLC (United Kingdom) - Tecan Group AG (Switzerland) - Veracyte, Inc. (United States) - Vitrolife AB (Sweden) - Volcano Corporation (United States) For more information visit http://www.researchandmarkets.com/research/7d...da_focused
MMM: 149.90 (+0.42), COO: 137.62 (-4.37), SNN: 34.67 (-0.43), VCYT: 6.50 (+0.10), ABAX: 46.25 (+1.44), DYSL: 1.90 (+0.02), VOLC: 17.99 (+0.01), CLLS: 26.61 (-0.16), COHR: 57.81 (-0.32), HRC: 53.23 (+0.56)
100 R&D Intensive Medical Devices/Technology/Supplies Companies 2015
M2 - Wed Apr 15, 8:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gjbtw4/randd_intensive) has announced the addition of the "R&D Intensive Medical Devices/Technology/Supplies 100 - An Industry Report" report to their offering. This newly launched report identifies 100 R&D Intensive medical devices/technology/supplies companies and covers various aspects of these 100 companies including news, financial/non-financial information, and stock market analysis. Over the past few years the way the medical devices industry assesses innovation and new technology has changed. The old dynamic of the physician as judge of value has been replaced with the government, private insurers, and consumers increasingly determining what sells and at what price point. Consumers refuse to pay for incremental enhancements that add bells and whistles that do not improve health or reduce cost. The faster, better, smaller, cheaper innovations in medical devices are the devices that will maintain a sustainable advantage. Recently, global market has been taking the lead in developing lean, frugal, and reverse innovation. This type of innovation simplifies devices and processes, retaining essential functions, while applying new technologies that are more versatile, mobile, and adaptable to consumer's needs and are less expensive. The global companies in medical devices/technology industry are highly R&D intensive and technology based. Such companies, on an average, spend 12% of their revenues on R&D each year in order to develop, design, and commercialize innovative medical devices. With this special industry report, our endeavor is to provide the new investors globally with a complete resourceful research report for familiarizing with the present investment trends of the R&D Intensive companies in the medical industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - R&D Intensive 100 medical devices/technology/supplies companies - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances of R&D Intensive medical devices/technology/supplies companies with foreign companies - International presence of R&D Intensive medical devices/technology/supplies companies - Key R&D activities by R&D Intensive medical devices/technology/supplies companies Key Topics Covered: 1: Rankings of R&D Intensive Medical Devices/Technology/Supplies Companies 2: Stock Market Performance over 5 Years: Leading 25 R&D Intensive Medical Devices/Technology/Supplies Companies 3: Key News of R&D Intensive Medical Devices/Technology/Supplies Companies for Year 2014 4: Important Alliances of R&D Intensive Medical Devices/Technology/Supplies Companies with Foreign Companies 5: Research and Development Activities by R&D Intensive Medical Devices/Technology/Supplies Companies 6: International Presence of R&D Intensive Medical Devices/Technology/Supplies Companies 7: Mergers and Acquisitions of R&D Intensive Medical Devices/Technology/Supplies Companies Companies Mentioned - Partial List - 3 D Matrix Ltd. (Japan) - aap Implantate AG (Germany) - Abcam Plc (United Kingdom) - Advanced Oncotherapy PLC (United Kingdom) - Aerocrine Ab (Sweden) - Alphatec Holdings, Inc. (United States) - Analytica Limited (Australia) - Angiodynamics, Inc. (United States) - Animalcare Group Plc (United Kingdom) - Ansell Limited (Australia) - Astrazenca Plc (United Kingdom) - Avacta Group Plc (United Kingdom) - Avita Medical Limited (Australia) - Avita Medical Europe Limited (United Kingdom) - Axogen Inc. (United States) - Becton, Dickinson and Company (United States) - Bio Rad Laboratories Incorporated (United States) - Bluechiip Limited (Australia) - Bovie Medical Corporation (United States) - Brain Resource Ltd (Australia) - Exiqon A/S (Denmark) - FEI Company (United States) - Great Basin Scientific Inc. (United States) - Integra LifeSciences Holdings Corporation (United States) - Lifewatch AG (Switzerland) - Mazor Robotics Limited (Israel) - Sekisui Medical Co., Ltd. (Japan) - Simavita Ltd. (Australia) - Sorin SpA (Italy) - Zeltiq Aesthetics Inc. (United States) For more information visit http://www.researchandmarkets.com/research/gj..._intensive
ATEC: 0.34 (-0.02), GBSNU: 16.22 (-0.28), MZOR: 11.60 (+0.03), FEIC: 77.20 (-0.02), ZLTQ: 31.72 (+0.04), IART: 58.79 (+0.44), BVX: 2.10 (+0.04)
GeoSpock Limited Completes £782,500 ($1,245,350) Fundraising and Enters the TechStars Global Startup Accelerator
PR Newswire - Mon Nov 10, 3:47AM CST
UK geosearch tech firm raises cash to commercialise its GeoWarp(TM), Collide(TM) and Collide App Designer(TM) platforms that enable businesses wishing to take advantage of growing trends in the internet-of-things, big-data and multi-dimensional, real-time geospatial experiences.
ABC: 92.84 (-0.70)
